Article info

Download PDFPDF
An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

Authors

  1. Address correspondence and reprint requests to Nicoletta Colombo, MD, Istituto Europeo di Oncologia (IEO), Milan, Italy, Via Ripamonti, 435-20141 Milano. E-mail: nicoletta.colombo@ieo.it.

Citation

Parma G, Mancari R, Del Conte G, et al
An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

Publication history

  • Received October 26, 2011
  • First published June 1, 2012.
Online issue publication 
June 01, 2012

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.